Advancing Pharmacogenomics in the UK
More than 20 years ago, the Human Genome Project mapped the genes that make us who we are, paving the way for using information about an individual’s genes in healthcare. ‘Pharmacogenomics’ studies how our genes influence our response to medicines. We know that differences in our genes can determine whether a medicine works well, fails to work, or causes series side effects. Pharmacogenomic knowledge is now at a stage where it can benefit people receiving medical treatment.
The Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx) is dedicated to accelerating the safe and effective use of pharmacogenomics in healthcare. We develop guidelines, industry pathways, and educational platforms to support regulators, healthcare professionals, and researchers, while ensuring patient and public input shapes the future of genomic medicine.
Through collaboration across academia, industry, and the NHS, our goal is to make precision medicine a reality, improving patient outcomes and fostering innovation across the UK.
Contact:
Angela Cucchi, Project Co-Ordinator, angela.cucchi@liverpool.ac.uk
Our supporting partners:
What is CERSI-PGx?
-
CERSI-PGx 5th Guideline is published!
We are pleased to share the news that our guideline on MT-RNR1 genotype testing for preventing aminoglycoside-mediated ototoxicity has been published in the BCJP. Huge…
-
Understanding public perspectives on direct-to-consumer pharmacogenomic testing in the UK: a qualitative study | The Pharmacogenomics Journal
We are delighted that our WP5 leads John McDermott and Ramona Moldovan along with colleagues have published an article in the Pharmacogenomics Journal. DTC PGx…
-
The UK Industry PGx Regulatory Portal Product Discovery Report
Presents a comprehensive analysis and vision for a digital regulatory portal designed to streamline the compliance journey for pharmacogenomic (PGx) testing companies within the UK…
Read more News & Events articles →